“Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026” Report Highlights:
- Global C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion
- Global C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)
- Global C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)
- Commercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)
- Soliris (Eculizumab) Sales In 2020: > USD 3 Billion
“Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 3 commercially available C5 Complement Inhibitors with their regional level revenue, market share and the clinical profile.
Global pharmaceutical marketplace is undergoing subtle changes with respect to the need of the patient population. The entire pharmaceutical industry is packed with effective therapeutics against different types of diseases and eventually the availability of hundreds of therapies and thousands of therapeutic agents in the commercial market has eventually made the global pharmaceutical market worth trillion-dollar size. Although, the global pharmaceutical market is packed with excessive number of therapies, but for the development of the market to an extensive level, researchers have come across with a novel and impressive therapeutic class known as C5 complement inhibitor therapy which targets one of the most important immune system pathways.
The arrival of C5 complement inhibitor drug market for the need of the patient population all over the world is believed to be capable of bearing all the challenges that the pharmaceutical industry has been witnessing for long period of time. Not only cancer, but the therapeutic approach developed by the researchers few years back is believed to be having subtle impact on several different kidney diseases and many more that have huge mortality rate. Over a small period of time, the respective therapeutic approach is also being focused by some of the big pharmaceutical players which indeed have led to a traditional increase in the rate of research and development activities for the same.
It is predicted that in the next few years of time period, the entire therapeutic approach which at the current period of time is only having few clinical drugs will be packed with excessive number of inhibitors, driving the way of the respective therapy market to become one of the pioneering leaders. Some of the parameters that are estimated to get improved with coming time for the substantial improvement of the overall therapy are: R&D productivity, inhibitor cost reduction, as well as influx of major pharmaceutical players and biotech companies, focused towards adapting the therapeutic approach for further investigation against different diseases with high mortality and prevalence rate.
“Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026” report findings, it is predicted that the therapeutic approach despite of being completely novel, when compared with other old and traditional therapies is accelerating at a very high rate with respect to market size and opportunities. In addition, the global sales of the C5 complement inhibitor drug market is growing at steadily, apparently depicting the increase in the consumption rate of the drugs by the patients. Exclusive demand of the therapeutic approach such as C5 complement inhibitor therapy and the presence of few inhibitor drugs in the market is also predicted to align the entire market toward becoming more dynamic and drastic. It is predicted that in the next few years, several investigational drugs will enter late-stage clinical development phase, which will eventually cause a projectile inclination in the rate of market growth and opportunities highly lacking in the current pharmaceutical industry.
Table of Contents
1. Introduction to C5 Complement Inhibitors
1.1 Overview
1.2 Evolution of C5 Complement Inhibitors
2. Mechanism of C5 Complement Inhibitors
2.1 Mechanism of Complement Activation
2.2 Inhibition of C5 Complement
3. Global C5 Complement Inhibitors Market Sales Insight
3.1 Current Market Scenario
3.2 Future Market Opportunity
3.3 Market Opportunity by Indication
3.3.1 Paroxysmal Nocturnal Hemoglobinuria
3.3.2 Atypical Hemolytic Uremic Syndrome
3.3.3 Neuromyelitis Optica Spectrum Disorder
3.3.4 Generalized Myasthenia Gravis
4. Global C5 Complement Inhibitors Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Patient Segment
4.4 By Phase
5. US - C5 Complement Inhibitors Market Analysis
5.1 Current Market Scenario
5.2 Future Market Opportunity
6. Europe - C5 Complement Inhibitor Market Analysis
6.1 Current Market Scenario
6.2 Future Market Opportunity
7. Asia Pacific - C5 Complement Inhibitor Market Analysis
7.1 Current Market Scenario
7.2 Future Market Opportunity
8. Soliris (Eculizumab)
8.1 Overview
8.2 Patent Exclusivity & Designations
8.3 Dosage & Price Analysis
8.3.1 Branded (Soliris)
8.3.2 Biosimilar (Elizaria)
8.4 Global Sales Analysis
8.5 Soliris Regional Sales Analysis
8.5.1 US
8.5.2 Europe
8.5.3 Asia Pacific
8.5.4 Rest of World
9. Ultomiris (Ravulizumab)
9.1 Overview
9.2 Patent Exclusivity & Designation
9.3 Dosage & Price Analysis
9.4 Global Sales Analysis
9.5 Soliris Regional Sales Analysis
9.5.1 US
9.5.2 Europe
9.5.3 Asia Pacific
9.5.4 Rest of World
10. Global C5 Complement Inhibitors Clinical Trials Insight
10.1 Preclinical
10.2 Phase-I
10.3 Phase-II
10.4 Phase-II/III
10.5 Phase-III
11. Marketed C5 Complement Inhibitors Clinical Insight
11.1 Eculizumab
11.2 Ravulizumab
11.3 Eculizumab Biosimilar
12. C5 Complement Inhibitors Market Dynamics
12.1 C5 Complement Inhibitors Market Drivers
12.2 Challenges for C5 Complement Inhibitor Market
13. C5 Complement Inhibitor Market Future Outlook
14. Competitive Landscape
14.1 Amgen
14.2 Akari Therapeutics
14.3 CANbridge Pharmaceuticals
14.4 ChemoCentryx
14.5 Generium
14.6 IVERIC Bio
14.7 Novartis
14.8 Roche
14.9 Samsung Bioepis
14.10 UCB
List of Figures
Figure 1-1: Therapeutic Areas of C5 Complement Inhibitors
Figure 1-2: History of C5 Complement Inhibitors
Figure 2-1: Mechanism of Complement Activation
Figure 2-2: Role of C5 Complement in Regulation of Various Functions
Figure 2-3: Mechanism of Action of Eclizumab
Figure 3-1: Global - C5 Complement inhibitors Market Size (US$ Billion), 2017-2020
Figure 3-2: Global - C5 Complement inhibitors Market Size by Region (US$ Billion), 2020
Figure 3-3: Global - C5 Complement inhibitors Market Size by Region (%), 2020
Figure 3-4: Global - C5 Complement Inhibitors Market Size v/s Total Orphan Drug Market (US$ Billion), 2020
Figure 3-5: Global - C5 Complement Inhibitors Market Size v/s Others Orphan Drug Market (%), 2020
Figure 3-6: Global - C5 Complement Inhibitors Market Size by Product (US$ Billion), 2020
Figure 3-7: Global - C5 Complement Inhibitors Market Size by Product (%), 2020
Figure 3-8: Global - C5 Complement Inhibitors Market Opportunity (US$ Billion), 2020-2026
Figure 3-9: Global - Orphan Drugs Market Size (US$ Billion), 2020-2026
Figure 3-10: Global - Soliris Sales Forecast (US$ Billion), 2020-2026
Figure 3-11: Global - Ultomiris Sales Forecast (US$ Billion), 2020-2026
Figure 3-12: Global - Estimated Paroxysmal Nocturnal Hemoglobinuria Cases, 2020-2026
Figure 3-13: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 5% Adaptation Rate (US$ Million), 2021-2026
Figure 3-14: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 10% Adaptation Rate (US$ Million), 2021-2026
Figure 3-15: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 15% Adaptation Rate (US$ Million), 2021-2026
Figure 3-16: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 20% Adaptation Rate (US$ Million), 2021-2026
Figure 3-17: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 25% Adaptation Rate (US$ Million), 2021-2026
Figure 3-18: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 30% Adaptation Rate (US$ Million), 2021-2026
Figure 3-19: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 35% Adaptation Rate (US$ Million), 2021-2026
Figure 3-20: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 40% Adaptation Rate (US$ Million), 2021-2026
Figure 3-21: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 45% Adaptation Rate (US$ Million), 2021-2026
Figure 3-22: Global - Paroxysmal Nocturnal Hemoglobinuria Targeting C5 Complement Inhibitors Market Opportunity by 50% Adaptation Rate (US$ Million), 2021-2026
Figure 3-23: Global - Estimated Atypical Hemolytic Uremic Syndrome Cases, 2020-2026
Figure 3-24: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 5% Adaptation Rate (US$ Million), 2021-2026
Figure 3-25: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 10% Adaptation Rate (US$ Million), 2021-2026
Figure 3-26: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 15% Adaptation Rate (US$ Million), 2021-2026
Figure 3-27: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 20% Adaptation Rate (US$ Million), 2021-2026
Figure 3-28: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 25% Adaptation Rate (US$ Million), 2021-2026
Figure 3-29: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 30% Adaptation Rate (US$ Million), 2021-2026
Figure 3-30: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 35% Adaptation Rate (US$ Million), 2021-2026
Figure 3-31: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 40% Adaptation Rate (US$ Million), 2021-2026
Figure 3-32: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 45% Adaptation Rate (US$ Million), 2021-2026
Figure 3-33: Global - Atypical Hemolytic Uremic Syndrome Targeting C5 Complement Inhibitors Market Opportunity by 50% Adaptation Rate (US$ Million), 2021-2026
Figure 3-34: Global - Neuromyelitis Optica Spectrum Disorder Cases, 2020-2026
Figure 3-35: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 2% Adaptation Rate (US$ Million), 2021-2026
Figure 3-36: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 4% Adaptation Rate (US$ Million), 2021-2026
Figure 3-37: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 6% Adaptation Rate (US$ Million), 2021-2026
Figure 3-38: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 8% Adaptation Rate (US$ Million), 2021-2026
Figure 3-39: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 10% Adaptation Rate (US$ Million), 2021-2026
Figure 3-40: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 12% Adaptation Rate (US$ Million), 2021-2026
Figure 3-41: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 14% Adaptation Rate (US$ Million), 2021-2026
Figure 3-42: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 16% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-43: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 18% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-44: Global - Neuromyelitis Optica Spectrum Disorder Targeting C5 Complement Inhibitors Market Opportunity by 20% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-45: Global - Generalized Myasthenia Gravis Cases, 2020-2026
Figure 3-46: Global - Generalized Myasthenia Gravis Targeting C5 Complement Inhibitors Market Opportunity by 1% Adaptation Rate (US$ Million), 2021-2026
Figure 3-47: Global - Generalized Myasthenia Gravis Targeting C5 Complement Inhibitors Market Opportunity by 2% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-48: Global - Generalized Myasthenia Gravis Targeting C5 Complement Inhibitors Market Opportunity by 3% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-49: Global - Generalized Myasthenia Gravis Targeting C5 Complement Inhibitors Market Opportunity by 4% Adaptation Rate (US$ Billion), 2021-2026
Figure 3-50: Global - Generalized Myasthenia Gravis Targeting C5 Complement Inhibitors Market Opportunity by 5% Adaptation Rate (US$ Billion), 2021-2026
Figure 4-1: Global - C5 Complement Inhibitors Clinical Trials by Company (Number of Trials), 2021 Till 2026
Figure 4-2: Global - C5 Complement Inhibitors Clinical Trials by Country (Number of Trials), 2021 Till 2026
Figure 4-3: Global - C5 Complement Inhibitors Clinical Trials by Patient Segment (Number of Trials), 2021 Till 2026
Figure 4-4: Global - C5 Complement Inhibitors Clinical Trials by Phase (Number of Drugs), 2021 Till 2026
Figure 5-1: US - C5 Complement inhibitors Market Size (US$ Billion), 2017-2020
Figure 5-2: US - C5 Complement Inhibitors Market Size by Product (US$ Billion), 2020
Figure 5-3: US - C5 Complement Inhibitors Market Size by Product (%), 2020
Figure 5-4: US - C5 Complement Inhibitors Market Opportunity (US$ Billion), 2020-2026
Figure 5-5: US - Soliris Sales Forecast (US$ Billion), 2020-2026
Figure 5-6: US - Ultomiris Sales Forecast (US$ Billion), 2020-2026
Figure 6-1: Europe - C5 Complement inhibitors Market Size (US$ Billion), 2017-2020
Figure 6-2: Europe - C5 Complement Inhibitors Market Size v/s Total Orphan Drug Market (US$ Billion), 2020
Figure 6-3: Europe - C5 Complement Inhibitors Market Size v/s Others Orphan Drug Market (%), 2020
Figure 6-4: Europe - C5 Complement Inhibitors Market Size by Product (US$ Billion), 2020
Figure 6-5: Europe - C5 Complement Inhibitors Market Size by Product (%), 2020
Figure 6-6: Europe - C5 Complement Inhibitors Market Opportunity (US$ Billion), 2020-2026
Figure 6-7: Europe - Orphan Drugs Market Size (US$ Billion), 2020-2026
Figure 6-8: Europe - Soliris Sales Forecast (US$ Million), 2020-2026
Figure 6-9: Europe - Ultomiris Sales Forecast (US$ Million), 2020-2026
Figure 7-1: Asia Pacific - C5 Complement inhibitors Market Size (US$ Billion), 2017-2020
Figure 7-2: Asia Pacific - C5 Complement Inhibitors Market Size v/s Total Orphan Drug Market (US$ Billion), 2020
Figure 7-3: Asia Pacific - C5 Complement Inhibitors Market Size v/s Others Orphan Drug Market (%), 2020
Figure 7-4: Asia Pacific - C5 Complement Inhibitors Market Size by Product (US$ Million), 2020
Figure 7-5: Asia Pacific - C5 Complement Inhibitors Market Size by Product (%), 2020
Figure 7-6: Asia Pacific - C5 Complement Inhibitors Market Opportunity (US$ Billion), 2020-2026
Figure 7-7: Asia Pacific - Orphan Drugs Market Size (US$ Billion), 2020-2026
Figure 7-8: Asia Pacific - Soliris Sales Forecast (US$ Million), 2020-2026
Figure 7-9: Asia Pacific - Ultomiris Sales Forecast (US$ Million), 2020-2026
Figure 8-1: Soliris - US FDA Approval Year by Indication
Figure 8-2: Soliris - Approval Year by Region
Figure 8-3: Soliris - Patent Expiration Year By Region
Figure 8-4: US - Soliris Orphan Exclusivity Expiration Year by Indication
Figure 8-5: Europe - Soliris Orphan Exclusivity Expiration Year by Indication
Figure 8-6: Japan - Soliris Orphan Exclusivity Expiration Year by Indication
Figure 8-7: US - Price for 30ml Supply & Price Per ml of Soliris Intravenous Solution (US$), April’2021
Figure 8-8: UK - Price for 30ml Supply & Price Per ml of Soliris Intravenous Solution (GBP/US$), April’2021
Figure 8-9: India - Price for 30ml Supply & Price Per ml of Soliris Intravenous Solution (INR/US$), April’2021
Figure 8-10: Korea - Price for 30ml Supply & Price Per ml of Soliris Intravenous Solution (KRW/US$), April’2021
Figure 8-11: Soliris - Treatment Cost For Paroxysmal Nocturnal Hemoglobinuria (US$), April’2021
Figure 8-12: Soliris - Treatment Cost For aHUS, gMG & NMOSD (US$), April’2021
Figure 8-13: Russia - Price for 30ml Supply & Price Per ml of Soliris Intravenous Solution (RUR/US$), April’2021
Figure 8-14: Global - Soliris Sales (US$ Million), 2017 - 2020
Figure 8-15: Global - Soliris Sales by Region (US$ Million), 2020
Figure 8-16: Global - Soliris Sales by Region (%), 2020
Figure 8-17: Global - Soliris Quarterly Sales Value (US$ Million), April’2021
Figure 8-18: US - Soliris Sales (US$ Million), 2017 - 2020
Figure 8-19: US - Soliris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 8-20: Europe - Soliris Sales (US$ Million), 2017 - 2020
Figure 8-21: Europe - Soliris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 8-22: Asia Pacific - Soliris Sales (US$ Million), 2017 - 2020
Figure 8-23: Asia Pacific - Soliris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 8-24: ROW - Soliris Sales (US$ Million), 2017 - 2020
Figure 8-25: ROW - Soliris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 9-1: Ultomiris - US FDA Approval Year by Indication
Figure 9-2: Ultomiris - Approval Year by Region
Figure 9-3: Ultomiris - Approval & Patent Expiration Year
Figure 9-4: Ultomiris - Orphan Designation Expiration Year by Region
Figure 9-5: Europe - Ultomiris Orphan Designation Issue & Withdrawal Year
Figure 9-6: US - Price for 30ml Supply & Price Per ml of Ultomiris 10mg/ml Intravenous Solution (US$), April’2021
Figure 9-7: US - Price for 3ml Supply & Price Per ml of Ultomiris 100mg/ml Intravenous Solution (US$), April’2021
Figure 9-8: US - Price for 11ml Supply & Price Per ml of Ultomiris 100mg/ml Intravenous Solution (US$), April’2021
Figure 9-9: UK - Price for 30ml Supply & Price Per ml of Ultomiris Intravenous Solution (GBP/US$), April’2021
Figure 9-10: Germany - Price for 30ml Supply & Price Per ml of Ultomiris 10mg/ml Intravenous Solution (EUR/US$), April’2021
Figure 9-11: Germany - Price for 3ml Supply & Price Per ml of Ultomiris 100mg/ml Intravenous Solution (EUR/US$), April’2021
Figure 9-12: Germany - Price for 11ml Supply & Price Per ml of Ultomiris 100mg/ml Intravenous Solution (EUR/US$), April’2021
Figure 9-13: Ultomiris - Loading Dose by Body Weight for Paroxysmal Nocturnal Hemoglobinuria (mg)
Figure 9-14: Ultomiris - Maintenance Dose by Body Weight for Atypical Hemolytic Uremic Syndrome (mg/8 Weeks)
Figure 9-15: Ultomiris - Loading & Maintenance Dose by Body Weight for Atypical Hemolytic Uremic Syndrome (mg/4Weeks)
Figure 9-16: Ultomiris - Loading & Maintenance Dose by Body Weight for Atypical Hemolytic Uremic Syndrome (mg/4Weeks)
Figure 9-17: Global - Ultomiris Sales (US$ Million), 2019 & 2020
Figure 9-18: Global - Ultomiris Sales by Region (US$ Million), 2020
Figure 9-19: Global - Ultomiris Sales by Region (%), 2020
Figure 9-20: Global - Ultomiris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 9-21: US - Ultomiris Sales (US$ Million), 2019 & 2020
Figure 9-22: US - Ultomiris Quarterly Sales Value (US$ Million), 2019 & 2020
Figure 9-23: Europe - Ultomiris Sales (US$ Million), 2019 & 2020
Figure 9-24: Europe - Ultomiris Quarterly Sales Value (US$ Million), 2020
Figure 9-25: Asia Pacific - Ultomiris Sales (US$ Million), 2019 & 2020
Figure 9-26: Asia Pacific - Ultomiris Quarterly Sales Value (US$ Million), 2020
Figure 9-27: ROW - Ultomiris Quarterly Sales Value (US$ Million), 2020
Figure 12-1: Global - C5 Complement Inhibitors Market Drivers
Figure 12-2: Challenges for Global C5 Complement Inhibitors Market
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen
- Akari Therapeutics
- CANbridge Pharmaceuticals
- ChemoCentryx
- Generium
- IVERIC Bio
- Novartis
- Roche
- Samsung Bioepis
- UCB
